Cancer drugs that keep tumors from growing may not lead to better quality of life for patients, a new study suggests.
“In countries where patients need to pay co-pays, they can use up all their savings in order to get access to those expensive new drugs and in the end, they may not extend their lives or improve their quality of life,” Feng Xie, a professor of health economics at McMaster University, told Reuters Health.
These days, cancer researchers and drug companies often use progression-free survival as a measure of a new drug’s effectiveness, Xie explained by phone.
“In the past, when a new drug was developed, overall survival” – that is, how long the patient lived – “was the endpoint to evaluate. A lot of drugs have now been approved based on the benefit of progression-free survival,” Xie said.
NJ MAN DIES AFTER CONTRACTING BRAIN-EATING PARASITE
One reason for using progression-free survival as a marker of effectiveness is that it can be measured sooner than overall survival, so new drugs can make it through the pipeline quicker, Xie and colleagues explain in JAMA Internal Medicine.
The problem, Xie said, is that progression-free survival, measured in the short term, doesn’t necessarily predict longer life. And as the new study shows, it may also fail to predict better quality of life.
Data pooled from all 38 studies showed no significant association between progression-free survival and quality of life.
The researchers had difficulty comparing data from the studies because quality of life was not always measured in the same way. Xie hopes that in the future, researchers will standardize the way they measure quality of life.
JAMES ALLISON, TASUKU HONJO WIN NOBEL FOR CANCER RESEARCH
Dr. Robert Ferris, director of the Hillman Cancer Center at the University of Pittsburgh Medical Center, isn’t ready to throw out progression-free survival as an indicator of a cancer drug’s effectiveness. But the early marker may under- or over-estimate the worth of a medication, Ferris said in a phone interview.
Still, progression-free survival can be used as an early indicator that researchers are on the right track with a new drug, Ferris said. When an experimental drug does a good job of controlling a tumor, for example, that might give researchers the impetus to conduct larger-scale trials.